Lilly to sell heartworm line for Novartis deal approval
Eli Lilly and Co. wants to combine Novartis with its own animal health business, Elanco, to create the second-largest animal health company in the U.S.
Eli Lilly and Co.
Articles
Lilly reaches insulin development deal with Adocia
Eli Lilly and Co. could pay more than $570 million to French pharmaceutical company Adocia under an agreement to develop a fast-acting insulin that is in the early stages of clinical testing.
Lilly bumps up dividend for first time since 2009
Shares of Eli Lilly and Co. were on the rise Tuesday morning, a day after the drugmaker announced its first dividend increase in more than five years.
Lilly’s Cyramza gets new marketing approval
Eli Lilly and Co.'s drug Cyramza has been approved as a treatment for lung cancer, regulators said. The Food and Drug Administration is allowing Lilly to market the drug as a treatment for cases that have spread.
Alzheimer’s tests present dilemma of knowing the future
While the tests will likely help drug companies like Eli Lilly and Co. evaluate medicines, they’ll also create wrenching personal and ethical dilemmas for patients who will have to live with the knowledge that they’re destined to develop the disease.
Covance shareholder sues over $6.1B LabCorp deal
A Covance Inc. investor contends in a lawsuit that the drug-testing company’s board erred in relying on what the shareholder called Goldman Sachs Group Inc.’s conflict-tainted advice. Covance has major laboratory operations in Indianapolis.
Lilly rheumatoid arthritis drug meets goals in final-stage trial
If approved, Baricitinib may bring Lilly $673 million in 2020, according to the average of five analysts’ estimates compiled by Bloomberg.
Feds drop case against former Lilly scientists accused of stealing secrets
Federal prosecutors dropped all charges against two scientists accused of stealing trade secrets worth $55 million from Eli Lilly and Co. after new information emerged last month, according to a court motion made Friday.
Lilly competitor claims early success with Alzheimer’s drug
Biogen Idec Inc. shares rose Tuesday after the company said its Alzheimer’s drug showed promising early results and will be quickly moved into a final-stage trial.
Lilly in $440M osteoporosis patch deal with Zosano
Eli Lilly and Co. said Tuesday it will team up with Zosano Pharma Corp. on an experimental osteoporosis patch in a deal that could be worth more than $440 million.
Fifth person pleads guilty in Lilly warehouse heist
Prosecutors say the theft from an Eli Lilly and Co. warehouse in Connecticut involved up to $100 million in prescription drugs.
New type of cholesterol drug shows promise in study
The results have immediate implications for 1 million Americans who suffer mild heart attacks or chest pain each year. They may also make it easier for other experimental medicines from companies such as Eli Lilly to reach patients.
Two plead guilty in $50M Lilly prescription drug theft
Prosecutors said the two men and three others broke into a Lilly warehouse in March 2010 and stole thousands of boxes of drugs, including Zyprexa, Cymbalta, Prozac and Gemzar.
Research firm Covance to be acquired in $6.1 billion deal
Covance manages clinical trials for drugmakers including locally-based Eli Lilly and Co. It employs about 1,500 workers in Indianapolis and Greenfield.
Alzheimer’s drug makes Avanir potential Lilly target
Eli Lilly and Co. would be a logical acquirer for the maker of a drug that could treat agitation in Alzheimer’s patients.
Eli Lilly donates $12.7 million to United Way
The donation represents the giving of employees and retirees of Lilly and Elanco Animal Health in the U.S. and Puerto Rico, plus a matching contribution from the Lilly Foundation.
Takeda, Lilly win 99-percent cut in Actos damages award
Judge Rebecca Doherty in Lafayette, Louisiana, said the jury’s decision to order Takeda to pay $6 billion and Lilly $3 billion was excessive and should be reduced to a total of $36.8 million.
Lilly adds $375M to Zymeworks partnership
Eli Lilly and Co. and Zymeworks said Wednesday that they are expanding a cancer drug development partnership.
Lilly third-quarter earnings fall below Wall Street’s expectations
The Indianapolis drugmaker's profit tumbled 58 percent as cheaper generic medicines took sales from blockbusters Cymbalta and Evista.
Eli Lilly to sell Puerto Rico manufacturing facility
The Indianapolis company said it is closing its Guayama facility because the patents on some of the drugs made there have expired.